immunotherapy

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer

Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold TumorsNANJING, China, Oct. 12, 2026 (GLOBE NEWSWIRE)...

Aetna Expands Bundled Oncology Prior Authorizations, Easing Provider Burden and Accelerating Member Access to Care

Oncology bundling to support all eligible Medicaid members for all cancer typesFull roll-out across all Aetna businesses in 2027Originally published...

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to KaziaSYDNEY, Sept. 22, 2026 /PRNewswire/ --...

Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate U.S. Growth and Oncology Innovation

Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance, execution and clinical capabilitiesSAN...

Israel National Biotech Innovation Center (INBI) Announces Official Launch and the Appointment of Anat Cohen-Dayag, PhD, as Chief Executive Officer of INBI Core

INBI is a transformational hub designed to unlock the value of Israel's world-class biomedical research and accelerate the development of...

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY®BiTco...

Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program

CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased...

error: Content is protected !!